(26%) and those who received the 4-drug regimen (25%) (p=0.73). There were also no statistically significant differences between those who maintained maximal virologic suppression, increases in CD4+ T-cell counts and adverse event occurrences between the groups. The study concluded that there was increased clinical benefit for one regimen over the other. As more than 80% of all patients maintained sustained virologic suppression for over 36 months, the addition of the fourth drug (the additional NRTI abacavir) appeared to provide no additional clinical benefit.
COMMENTARY
With the imminent availability of six different classes of medications for the treatment of HIV infection, the management of HIV-infected individuals has become more complex. Maximal suppression of HIV replication with antiretroviral therapy with immune recovery is the mainstay of initial treatment of HIV-infected individuals. The current standard of care includes initiation of therapy with three drugs, two NRTIs, and either a NNRTI or PI. No large clinical trial has addressed whether the addition of a fourth drug to this regimen will have any clinical benefit. The results of ACTG 5095 study clearly implies that there is no significant clinical advantage for the addition of abacavir to zidovudine/lamivudine and efavirenz in terms of virologic failure, immune recovery, or virologic suppression over 3 years of follow-up. Interestingly, addition of abacavir did not increase adverse events in this study.
Although this study addresses the important issue of augmenting an initial antiretroviral regimen to treat HIV-infected individuals, there are several important questions that still need to be answered. First, addition of a PI as the fourth agent may possibly provide superior virologic suppression to an initial regimen of two NRTIs and one NNRTI. Second, the development of more sensitive assays that can detect lower levels of HIV RNA in plasma have offered us a novel approach to evaluate adequate virologic suppression in vivo. Use of such assays in the context of augmenting initial antiretroviral therapy may be invaluable in better understanding the nature of viral suppression obtained by augmenting already potent antiviral regimens. Third, the effect of the addition of a fourth drug may also have an impact on the viral kinetics in the peripheral lymphocytes, but also on less wellcharacterized reservoirs such as lymph nodes and gut-associated lymphoid tissues. Studies that address the viral kinetics in these privileged compartments may be clinically useful in evaluating the long-term efficacy of augmentation of antiretroviral therapy.
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SUMMARY
Current standard of care for chronic hepatitis C infection using pegylated interferon and ribavirin is able to achieve a sustained virologic response in almost half of the treated patients. Sensitive assays that detect HCV RNA in plasma of these patients are critical in the management of chronic hepatitis C infection. HCV RNA testing during treatment helps clinicians make decisions regarding discontinuing therapy in patients in whom the likelihood of achieving a sustained virological response (SVR) is low. Current management guidelines recommend that therapy be stopped for those patients who do not suppress HCV RNA levels by two logs by week 12 or have detectable levels of HCV RNA by 24 weeks. However, such decisions are currently made using assays with a lower limit of detection of 100 IU/mL. Recently, several assays with greater sensitivity have been made available.
This study compared the Bayer Versant HCV RNA qualitative Assay based on transcription-mediated amplification (TMA) (with a lower limit of detection of 9.6 IU/mL) to the standard less sensitive PCR-based HCV-RNA assay to predict SVR with standard combination therapy. In this retrospective study, both TMA and PCR-based assays were used to detect HCV RNA from stored samples from patients in the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial. One thousand one hundred forty-five patients with bridging fibrosis or cirrhosis who were nonresponders to previous therapy with interferon with or without ribavirin were enrolled in this study and treated with Peginterferon alpha 2a 180 μg and ribavirin 1,000 to 1,200 mg per day. Three hundred seventy-three patients had undetectable levels of HCV RNA by week 20 and continued to receive the same treatment. Stored serum samples from these patients at week 12, 20, 24, and 48 were tested by TMA and PCR. The results indicate an excellent (99.9%) correlation between PCR and TMA for samples that were PCR-positive. Twenty-two percent of the PCR negative samples were TMApositive. A negative TMA test at week 12 and week 20 had a greater positive predictive value for SVR (82% and 66%, respectively) than did PCR testing. The earlier TMA became negative the better was the chance of achieving SVR. The study showed that negative TMA results at or after week 12 was superior to negative PCR results during treatment for predicting SVR. Persistently positive TMA results for persons with negative PCR were better predictors of an inability to achieve a SVR than was a single positive TMA.
COMMENTARY
This study highlights the importance of developing and testing sensitive HCV RNA detection assays that are capable of predicting SVR or lack thereof among those who undergo therapy for chronic hepatitis C infection. Although current standard of care yields a high rate of cure of HCV among HCV monoinfected patients, such high cure rates are not seen with patients with HIV/HCV coinfection. Furthermore, therapy by itself is associated with serious toxicities. Validation of tests that have better positive and negative predictive values is vital to focus treatment on those with the best chance of attaining a cure and minimizing drug-associated adverse events. This large study suggests that TMA is a better predictor for SVR and could be a useful test to monitor patients who undergo treatment for HCV.
The study was limited to a cohort of patients with severe liver disease. However, this study highlights the role of TMA assay in predicting SVR. Second, this study suggests that serial negative tests are better predictors of SVR than a single negative test. Routine use of TMA for management of HCV patients may require further prospective studies. Cost and availability of the assay may be limiting factors for widespread application of TMA assay. Other recent studies have suggested host factors may play a major role in predicting response to combination therapy and a 
SUMMARY
Before the advent of highly active antiretroviral therapy (HAART), cytomegalovirus (CMV) retinitis was a common opportunistic infection among patients with AIDS leading to visual acuity loss and blindness. Introduction of HAART has resulted in suppression of HIV replication and immune recovery leading to a decline in the incidence of opportunistic infections, including CMV retinitis. Most patients with sustained increases in CD4 T-cell counts over 100 cells/μL are able to discontinue anti-CMV therapy. However, the incidence of visual acuity loss among AIDS patients receiving HAART is largely unknown. This multicenter prospective observational study addresses the incidence of vision loss and the associated risk factors responsible for this among AIDS patients in the era of HAART.
This study examined 494 CMV-affected eyes in 379 HIV-infected patients with regular 3-month ophthalmologic monitoring. Examinations included visual acuity measurement, refraction studies, intraocular pressure monitoring, dilated indirect ophthalmoscopy, and fundus photography at every visit. Outcome measures included incidence of visual acuity loss to 20/50 or worse, to 20/200 or worse and of doubling of visual angle in eyes affected with CMV retinitis. All patients received HAART that consist of three or more antiretroviral drugs that included at least one HIV protease inhibitor or non-nucleoside reverse transcriptase inhibitor. Immune recovery was defined as an increase in CD4+ T-cell count by ≥50 cells/μl from a nadir CD4+ T-cell count to a level of 9100 cells/μl at enrollment. Over the course of the 3.1-year follow-up of the study, the incidence of visual acuity loss to 20/50 and 20/200 or worse were 29% and 15%, respectively. HAART-mediated immune recovery, as indicated by increases in CD4 T-cell counts, was associated with a 42% decrease in visual acuity loss to 20/50 or worse and a 61% decrease in visual acuity loss to 20/200 or worse. CMV retinitis in persons with AIDS continues to impose a substantial risk for incident visual acuity loss. However, patients with immune recovery from HAART have a 50% reduction in their risk for vision loss.
